GMP Solutions for Biotech & Cell and Gene Therapy

We provide Biotech GMP consulting and tailored solutions for cell and gene therapy companies navigating complex regulatory demands. Our senior consultants support you from clinical development to commercial manufacturing — ensuring compliance, accelerating product release, and building scalable Quality Systems for advanced therapies.

Discover how we support biotech innovators in achieving compliance, accelerating product release, and building robust quality systems for advanced therapies.

Our Core Services for Biotech and Advanced Therapies

Clinical-to-Commercial GMP Readiness

Transitioning from early clinical development to commercial manufacturing is one of the biggest challenges in biotech. Our biotech GMP services help you prepare for this shift by designing scalable Quality Systems, robust documentation practices, and risk-based oversight models. We ensure your clinical-to-commercial journey aligns with FDA, EMA, and Swissmedic expectations while maintaining efficiency and speed.

Regulatory & CMC Consulting (FDA & EMA)

Strong regulatory submissions require more than data — they require a clear CMC strategy. With our biotech regulatory and GMP consulting, we support IMPDs, INDs, BLAs, and MAAs by bridging science, manufacturing, and compliance. Our consultants ensure CMC dossier sections are inspection-ready and aligned with both U.S. and European health authority requirements, reducing regulatory risk and accelerating approvals.

QMS Design & Implementation for Clinical-stage Biotech

Many growing biotech companies inherit oversized or underdeveloped Quality Systems that don’t scale. We specialize in QMS design for biotech GMP compliance, creating fit-for-purpose frameworks that cover deviations, CAPAs, change control, and supplier qualification. Our focus is on lean systems that meet regulatory expectations without slowing your development timelines.

CDMO Evaluation, Qualification & Oversight

Relying on CDMOs is common in biotech — but oversight is often weak. We provide CDMO GMP oversight services that cover selection, qualification, and continuous supervision of your manufacturing partners. By establishing clear governance, risk-based monitoring, and structured escalation paths, we help ensure your CDMOs deliver GMP-compliant products while avoiding costly delays or compliance gaps.

Due Diligence Audits for Investors and Buyers

Biotech investors and buyers face high risks if GMP and operational gaps are missed. Our due diligence GMP audits identify compliance weaknesses, Quality risks, and remediation needs in acquisition targets. We provide clear, actionable reports that support valuation, negotiation, and post-deal integration — helping investors and strategic buyers make informed decisions with confidence.

Frequently Asked Questions

Biotech is moving fast. Is your GMP strategy keeping up?